The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination ...

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a ...

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March ...

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand ...

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor Relations ...

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...